Vol 27 (2024): Continuous Publishing
Clinical vignette
Published online: 2024-09-04
Carcinoid crisis induced by radioligand therapy: a rare but life-threatening complication in patient with neuroendocrine tumor
1
, 1, 1, 1, 1
, 1, 1, 1, 1
DOI: 10.5603/nmr.101934
Nucl. Med. Rev 2024;27:36-38.
Abstract
Carcinoid crisis (CC) is a rare but potentially life-threatening complication that may occur in patients with neuroendocrine tumor (NET). The pathophysiology of CC involves the sudden, massive release of vasoactive substances. This article presents a unique case study of a patient with a disseminated NET of the pancreas, who developed CC after radioligand therapy (RLT). Despite its rarity, awareness of CC as a potential severe complication of RLT is essential for timely and effective management and better prognosis for affected patients.
Keywords: carcinoid crisisneuroendocrine tumor (NET)radioligand therapy (RLT)somatostatin analogs (SSA)177Lu-DOTA-TATE
References
- Bardasi C, Benatti S, Luppi G, et al. Carcinoid crisis: a misunderstood and unrecognized oncological emergency. Cancers (Basel). 2022; 14(3).
- Gade AK, Olariu E, Douthit NT. Carcinoid syndrome: a review. Cureus. 2020; 12(3): e7186.
- Yadav SK, Jha CK, Patil S, et al. Lutetium therapy-induced carcinoid crisis: a case report and review of literature. J Cancer Res Ther. 2020; 16(Supplement): S206–S208.
- Tapia Rico G, Li M, Pavlakis N, et al. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two australian tertiary medical institutions. Cancer Treat Rev. 2018; 66: 1–6.
- Del Olmo-García MI, Muros MA, López-de-la-Torre M, et al. Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020; 9(7): 2203.
